Full Press Release Details
Structure Therapeutics
Reports First Quarter 2026 Financial Results and Recent Highlights
Reported positive results
from aleniglipron Phase 2 ACCESS II study
body weight loss, demonstrating highest efficacy among oral GLP-1RAs
time point and potentially comparable efficacy to injectable GLP1-RAs
OLE expected in Q3 2026;
Data from the Body Composition
and Type 2 Diabetes / Obesity data expected in Q4 2026
Positive end-of-Phase 2 feedback received from FDA;
Phase 3 initiation on track for Q3 2026
from Phase 1 single ascending dose (SAD) study of oral small molecule amylin
ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in
1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026
amylin and combination data to be presented
Diabetes Association (ADA) 86th Scientific Sessions in June 2026
Cash, cash equivalents
and short-term investments of $1.5 billion as of March 31, 2026,
cash runway through the end of 2028
SAN FRANCISCO, May 7, 2026-
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule
therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31,
2026, and provided a business update.
"With positive end of Phase 2
feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight
management in the third quarter," said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. "We are also looking forward to our aleniglipron
presentation along with presentations on our oral amylin and GLP-1 combination program at the upcoming ADA meeting. With our Phase
1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad
portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance
treatment, and fixed dose oral combinations for specific patient populations and expanded indications."
Recent and Upcoming Milestones
Aleniglipron - Oral Small Molecule
Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight
In March 2026, the Company reported data from the aleniglipron clinical program included
44-week topline data from the Phase 2 ACCESS II study, as well as interim data from body composition study and Phase 2b ACCESS open label
extension (OLE) study.
Data from the ACCESS, ACCESS II, Body
Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development.
The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.
The Company received positive end-of-Phase
2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with
a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program
The Company is also conducting supplementary
studies to enhance the competitive profile of aleniglipron, including:
Oral Small Molecule Amylin Receptor
Multiple presentations at ADA, taking
place from June 5-8, 2026
Details of the presentations are as
Title: ACCESS Trial: Dose-Ranging
Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with
Obesity and Overweight
Session: Oral Presentations -
Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making (1032-OR)
Speaker: Julio Rosenstock, MD,
University of Texas Southwestern Medical Center
Date: Friday, June 5: 12:45
Title: Safety, Tolerability,
and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
Session: General Poster Session
Date: Monday, June 8: 12:30
Title: Exploring a Lower Starting
Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials
Session: Late Breaking Poster
Date: Sunday, June 7: 12:30
Title: Combination Treatment
of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional
Weight Loss than Monotreatment in Obese NHPs
Session: Late Breaking Poster
Date: Sunday, June 7: 12:30
Title: Comparison of Conditioned
Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists
Session: Late Breaking Poster
Date: Sunday, June 7: 12:30
Additional information about the ADA
2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).
First Quarter 2026 Financial Highlights
Cash Position: Cash, cash equivalents
and short-term investments totaled $1.5 billion as of March 31, 2026. The Company received $100.0 million in the first quarter of
2026, consisting of an upfront license fee for certain patents that cover a class of oral GLP-1 receptor agonists that is different from
aleniglipron. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key
clinical milestones through the end of 2028. This includes costs related to the ongoing aleniglipron ACCESS OLE, ACCESS II extension
study, the supplementary studies, and Phase 3 registrational studies in chronic weight management, but excludes additional costs related
to pre-commercialization activities including commercial manufacturing.
Research and Development (R&D) Expenses: R&D
expenses for the first quarter of 2026 were $66.5 million, as compared to $42.9 million for the same period in 2025. The increase in
R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee
expenses (primarily due to an increase in personnel) to support the advancement of our GLP-1R franchise including aleniglipron.
General and Administrative (G&A)
Expenses: G&A expenses for the first quarter of 2026 were $22.9 million, as compared to $13.4 million for the same period in
2025. The increase in G&A expenses was primarily due to increases in employee expenses as we expanded our infrastructure to drive
and support the growth in our operations and professional services.
Net Loss: Net loss for the first
quarter of 2026 totaled $76.0 million, with non-cash share-based compensation expense of $11.6 million, compared to $46.8 million for
the same period in 2025 with non-cash share-based compensation expense of $5.9 million.
About Aleniglipron and Structure
Therapeutics' Oral Metabolic Franchise
Aleniglipron (GSBR-1290) is an investigational
orally-available, small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of obesity and T2DM. Through
Structure Therapeutics' structure-based drug discovery platform, aleniglipron was designed to be a biased G Protein-Coupled Receptor
(GPCR) agonist, which selectively activates the G-protein signaling pathway. Beyond aleniglipron, Structure Therapeutics is developing